Complications from computed tomography-guided core needle biopsy for patients receiving stereotactic body radiation therapy for early-stage lesions of the lung.

Abstract:

BACKGROUND:Obtaining a tissue diagnosis has traditionally been standard practice before initiating therapy for early-stage non-small-cell lung cancer (NSCLC). In several recent studies from Europe and Asia, a substantial proportion of patients have received stereotactic body radiation therapy (SBRT) based only on the imaging characteristics of the suspicious lesion. The underlying assumption is that the risk of percutaneous needle biopsy may outweigh the benefits in a population that generally has underlying pulmonary dysfunction and other medical comorbidity. Nevertheless, there is limited information regarding biopsy-related complication rates in high-risk patients with early-stage NSCLC who are treated with SBRT. MATERIALS AND METHODS:This was a retrospective review of outcomes after biopsy in patients treated with SBRT. Complications of percutaneous core needle biopsy were analyzed in relation to patient and tumor characteristics. Each biopsy event was analyzed independently for patients with multiple biopsies. RESULTS:A total of 112 percutaneous biopsies were performed in 103 patients. Pneumothorax of any degree was observed in 40 patients (35%) (95% CI, 27%-45%), and 12 patients (10.7%) had a clinically significant pneumothorax requiring chest tube placement (95% CI, 6%-18%). The time to first fraction of SBRT was not different in patients who had a pneumothorax or placement of a chest tube. On multivariate analysis, age, performance status, smoking history, pack-years of smoking, chronic obstructive pulmonary disease history, and forced expiratory volume in the first second of expiration were not statistically significantly associated with chest tube placement. CONCLUSION:Computed tomography-guided needle biopsy in a primarily medically inoperable patient population is safe, with an acceptable degree of complications.

journal_name

Clin Lung Cancer

journal_title

Clinical lung cancer

authors

Chowdhry VK,Chowdhry AK,Goldman N,Scalzetti EM,Grage RA,Bogart JA

doi

10.1016/j.cllc.2014.04.001

subject

Has Abstract

pub_date

2014-07-01 00:00:00

pages

302-6

issue

4

eissn

1525-7304

issn

1938-0690

pii

S1525-7304(14)00075-8

journal_volume

15

pub_type

杂志文章
  • The Controlling Nutritional Status Score Is a Significant Independent Predictor of Poor Prognosis in Patients With Malignant Pleural Mesothelioma.

    abstract:INTRODUCTION:Malignant pleural mesothelioma (MPM) is a devastating neoplasm; however, some patients exhibit a good response to chemotherapy or multidisciplinary therapy, including surgery and chemotherapy. It is therefore important to discover the factors that can be used to select patients who will benefit from such t...

    journal_title:Clinical lung cancer

    pub_type: 杂志文章

    doi:10.1016/j.cllc.2017.01.008

    authors: Takamori S,Toyokawa G,Taguchi K,Edagawa M,Shimamatsu S,Toyozawa R,Nosaki K,Seto T,Hirai F,Yamaguchi M,Shoji F,Okamoto T,Takenoyama M,Ichinose Y

    更新日期:2017-07-01 00:00:00

  • The Effect of Primary Care Physician Knowledge of Lung Cancer Screening Guidelines on Perceptions and Utilization of Low-Dose Computed Tomography.

    abstract:INTRODUCTION:Lung cancer screening (LCS) with low-dose computed tomography (LDCT) is recommended by the U.S. Preventive Services Task Force (USPSTF) in high-risk patients, but a minority of eligible people are screened. It is not clear whether knowledge of USPSTF recommendations among primary care physicians (PCP) affe...

    journal_title:Clinical lung cancer

    pub_type: 杂志文章

    doi:10.1016/j.cllc.2017.05.013

    authors: Raz DJ,Wu GX,Consunji M,Nelson RA,Kim H,Sun CL,Sun V,Kim JY

    更新日期:2018-01-01 00:00:00

  • Incidental Diagnosis of Asymptomatic Non-Small-Cell Lung Cancer: A Registry-Based Analysis.

    abstract:INTRODUCTION:Clinical manifestation of non-small-cell lung cancer (NSCLC) mainly occurs at advanced stages. Thus, the scientific community is evaluating different screening programs in high-risk patients to detect NSCLC at an earlier stage to improve survival. However, up to now patient selection and modalities have be...

    journal_title:Clinical lung cancer

    pub_type: 杂志文章

    doi:10.1016/j.cllc.2015.08.006

    authors: Kocher F,Lunger F,Seeber A,Amann A,Pircher A,Hilbe W,Fiegl M

    更新日期:2016-01-01 00:00:00

  • Multitargeted inhibitors in lung cancer: new clinical data.

    abstract::Novel therapies have been added to the treatment arsenal of physicians treating lung cancer in recent years. Most promising are agents that target the major pathways involved in cancer evolution, mostly proliferation and angiogenesis. Some of these treatments have been shown to synergize with traditional chemotherapy ...

    journal_title:Clinical lung cancer

    pub_type: 杂志文章,评审

    doi:10.3816/CLC.2008.s.014

    authors: Bar J,Herbst RS,Onn A

    更新日期:2008-01-01 00:00:00

  • External Validation of the New International Association for the Study of Lung Cancer Tumor, Node, and Metastasis 8th Edition Staging System and Updated T Descriptors in Determining Prognosis for Patients With Non-Small Cell Lung Cancer Patients With N3 D

    abstract:OBJECTIVE:The objective of this study is to externally validate the 8th Edition of the Tumor, Node, and Metastasis staging system and its updated T descriptors in patients with non-small cell lung cancer with N3 disease. METHODS:Data were extracted from the Surveillance, Epidemiology, and End Results database. Chi-squ...

    journal_title:Clinical lung cancer

    pub_type: 杂志文章

    doi:10.1016/j.cllc.2017.05.009

    authors: Shin JY,Yoon JK,Marwaha G

    更新日期:2017-11-01 00:00:00

  • Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients.

    abstract:BACKGROUND:Immune-related adverse events (irAEs) developed during immunotherapy with anti-PD-1 agents, could be a predictive surrogate marker of clinical benefit in patients with advanced non-small-cell lung cancer (NSCLC). METHODS:Patients with NSCLC, treated with anti-PD-1 agents, were retrospectively evaluated. Uni...

    journal_title:Clinical lung cancer

    pub_type: 杂志文章,多中心研究

    doi:10.1016/j.cllc.2019.02.006

    authors: Cortellini A,Chiari R,Ricciuti B,Metro G,Perrone F,Tiseo M,Bersanelli M,Bordi P,Santini D,Giusti R,Grassadonia A,Di Marino P,Tinari N,De Tursi M,Zoratto F,Veltri E,Malorgio F,Garufi C,Russano M,Anesi C,Zeppola T,

    更新日期:2019-07-01 00:00:00

  • Phase II trial of neoadjuvant chemotherapy using alternating doublets in non-small-cell lung cancer.

    abstract:PURPOSE:Lung cancer is an epidemic disease in developing countries. Incorporation of new active drugs in the neoadjuvant treatment of operable patients might lead to improved outcomes. Postchemotherapy mediastinal-based treatment decisions allow for in vivo testing of activity and could help to determine the ideal loca...

    journal_title:Clinical lung cancer

    pub_type: 杂志文章

    doi:10.3816/CLC.2007.n.003

    authors: Martins RG,Dienstmann R,de Biasi P,Dantas K,Santos V,Toscano E,Roriz W,Zamboni M,Sousa A,Small IA,Moreira D,Ferreira CG,Zukin M

    更新日期:2007-01-01 00:00:00

  • Modern Treatments in Advanced Non-Small-Cell Lung Cancer: Temporal Trends and Effect on Survival. A French Population-Based Study.

    abstract:UNLABELLED:Extrapolation of clinical trials results to the general population is always challenging. We analysed 1047 patients diagnosed with an advanced stage disease between 1998 and 2005 in a french administrative department and found a good spread of modern chemotherapy since 1998 and targeted therapy since 2002. M...

    journal_title:Clinical lung cancer

    pub_type: 杂志文章

    doi:10.1016/j.cllc.2015.05.001

    authors: Carpentier O,Selvaggi L,Jégu J,Purohit A,Prim N,Velten M,Quoix E

    更新日期:2015-11-01 00:00:00

  • Programmed Death-Ligand 1 Expression Predicts Tyrosine Kinase Inhibitor Response and Better Prognosis in a Cohort of Patients With Epidermal Growth Factor Receptor Mutation-Positive Lung Adenocarcinoma.

    abstract:BACKGROUND:The immune checkpoint proteins programmed death-1/ligand (PD-1/PD-L1) play a critical role in immune escape of tumor cells. In models of epidermal growth factor receptor (EGFR)-driven non-small-cell lung cancer (NSCLC), EGFR signal upregulates PD-1/PD-L1. However, data on the clinical significance of PD1/PD-...

    journal_title:Clinical lung cancer

    pub_type: 杂志文章

    doi:10.1016/j.cllc.2015.02.002

    authors: Lin C,Chen X,Li M,Liu J,Qi X,Yang W,Zhang H,Cai Z,Dai Y,Ouyang X

    更新日期:2015-09-01 00:00:00

  • Emerging antiangiogenic agents in lung cancer.

    abstract::The success of the anti-vascular endothelial growth factor (VEGF) antibody bevacizumab in numerous tumor types including non-small-cell lung cancer (NSCLC) has spurred the development of additional novel antiangiogenic agents with distinct mechanisms of action. These include the small-molecule receptor tyrosine kinase...

    journal_title:Clinical lung cancer

    pub_type: 杂志文章,评审

    doi:10.3816/CLC.2006.n.010

    authors: Lee D,Heymach JV

    更新日期:2006-03-01 00:00:00

  • Recurrent bronchial epithelial-myoepithelial carcinoma after local therapy.

    abstract::We present a rare case of recurrent multiple lesions of bronchial epithelial-myoepithelial carcinoma in a 74-year-old man treated with local resection. Two cellular types were found: epithelial cells and myoepithelial cells. The patient remains asymptomatic at 4-years of follow-up, supporting the fact that epithelial-...

    journal_title:Clinical lung cancer

    pub_type: 杂志文章

    doi:10.3816/CLC.2007.n.020

    authors: Muslimani AA,Kundranda M,Jain S,Daw HA

    更新日期:2007-05-01 00:00:00

  • Prognostic factors in the radical nonsurgical treatment of stage IIIB non-small-cell lung cancer.

    abstract:BACKGROUND:Many patients diagnosed with stage IIIB (AJCC sixth edition; T4, N3, or both; no pleural effusion) non-small-cell lung cancer (NSCLC) are treated with curative intent, despite a low cure rate. Guidelines are required to help select patients for radical therapy so that the patients with little chance of cure ...

    journal_title:Clinical lung cancer

    pub_type: 杂志文章

    doi:10.1016/j.cllc.2013.12.007

    authors: Russell K,Healy B,Pantarotto J,Laurie SA,MacRae R,Sabri E,Wheatley-Price P

    更新日期:2014-05-01 00:00:00

  • Phase I and II trials of vinorelbine with carboplatin for patients 75 years of age or older with previously untreated non-small-cell lung cancer.

    abstract:BACKGROUND:The safety and efficacy of platinum-based combination chemotherapy for elderly patients with advanced non-small-cell lung cancer (NSCLC) remains unclear. We conducted phase I and phase II trials of a combination of vinorelbine and carboplatin for patients ≥75 years of age and with advanced NSCLC. PATIENTS A...

    journal_title:Clinical lung cancer

    pub_type: 杂志文章

    doi:10.1016/j.cllc.2011.11.007

    authors: Takatani H,Nakamura Y,Nagashima S,Soda H,Kinoshita A,Fukuda M,Fukuda M,Soejima Y,Kasai T,Nakatomi K,Iida T,Oka M,Tsukamoto K,Kohno S

    更新日期:2012-09-01 00:00:00

  • Reliability of Small Biopsy Samples Compared With Resected Specimens for the Determination of Programmed Death-Ligand 1 Expression in Non--Small-Cell Lung Cancer.

    abstract:BACKGROUND:Several studies have assessed the expression of programmed death-ligand 1 (PD-L1) in resected surgical specimens of non-small-cell lung cancer (NSCLC). However, the expression of PD-L1 in smaller biopsy samples of advanced NSCLC has not been reported. PATIENTS AND METHODS:A total of 79 patients with NSCLC a...

    journal_title:Clinical lung cancer

    pub_type: 杂志文章

    doi:10.1016/j.cllc.2015.03.008

    authors: Kitazono S,Fujiwara Y,Tsuta K,Utsumi H,Kanda S,Horinouchi H,Nokihara H,Yamamoto N,Sasada S,Watanabe S,Asamura H,Tamura T,Ohe Y

    更新日期:2015-09-01 00:00:00

  • Effect of Thoracic Radiotherapy Timing and Fractionation on Survival in Nonmetastatic Small Cell Lung Carcinoma.

    abstract:BACKGROUND:The optimal timing of thoracic radiation therapy (RT) in relation to chemotherapy is unknown in the treatment of nonmetastatic small cell lung cancer (SCLC). We analyzed the National Cancer Data Base (NCDB) to assess the effect on overall survival (OS) of RT timing with chemotherapy for patients with SCLC. ...

    journal_title:Clinical lung cancer

    pub_type: 杂志文章

    doi:10.1016/j.cllc.2016.07.009

    authors: Wong AT,Rineer J,Schwartz D,Becker D,Safdieh J,Osborn V,Schreiber D

    更新日期:2017-03-01 00:00:00

  • Epidermal Growth Factor Receptor Mutational Testing and Erlotinib Treatment Among Veterans Diagnosed With Lung Cancer in the United States Department of Veterans Affairs.

    abstract:INTRODUCTION:We examined mutational testing of the epidermal growth factor gene (EGFR) and erlotinib treatment among veterans diagnosed with non-small-cell lung cancer in the United States Department of Veterans Affairs (VA). Our objectives were to identify the prevalence of clinically actionable EGFR mutations, to det...

    journal_title:Clinical lung cancer

    pub_type: 杂志文章

    doi:10.1016/j.cllc.2016.11.018

    authors: Lynch JA,Berse B,Chun D,Rivera D,Filipski KK,Kulich S,Viernes B,DuVall SL,Kelley MJ

    更新日期:2017-07-01 00:00:00

  • Weekly paclitaxel in elderly patients (aged > or = 70 years) with advanced non-small-cell lung cancer: an alternative choice? Results of a phase II study.

    abstract:PURPOSE:Paclitaxel and platinum-based chemotherapy is considered to be a standard approach for locally advanced and metastatic non-small-cell lung cancer (NSCLC). In recent years, weekly paclitaxel has been widely used for its safety profile, especially in breast and ovarian cancer. Otherwise, only a few studies are av...

    journal_title:Clinical lung cancer

    pub_type: 杂志文章

    doi:10.3816/CLC.2008.n.043

    authors: Rossi D,Dennetta D,Ugolini M,Alessandroni P,Catalano V,Fedeli SL,Giordani P,Casadei V,Baldelli AM,Graziano F,Catalano G

    更新日期:2008-09-01 00:00:00

  • Advancements in Small-cell Lung Cancer: The Changing Landscape Following IMpower-133.

    abstract::The treatment landscape of small-cell lung cancer is rapidly evolving. Results of the first-line randomized trial comparing etoposide/carboplatin/placebo with etoposide/carboplatin/atezolizumab (IMpower-133) were recently published, showing a longer progression-free survival and overall survival for patients receiving...

    journal_title:Clinical lung cancer

    pub_type: 杂志文章,评审

    doi:10.1016/j.cllc.2018.12.019

    authors: Pacheco J,Bunn PA

    更新日期:2019-05-01 00:00:00

  • Assessment of Selection Criteria for Low-Dose Lung Screening CT Among Asian Ethnic Groups in Taiwan: From Mass Screening to Specific Risk-Based Screening for Non-Smoker Lung Cancer.

    abstract:BACKGROUND:The National Lung Screening Trial (NLST) showed low-dose screening chest computed tomography (CT) reduced the lung cancer mortality rate up to 20% in high-risk patients in the United States. We aimed to investigate the impact of applying the NLST eligibility criteria to the population in Taiwan, and to ident...

    journal_title:Clinical lung cancer

    pub_type: 杂志文章

    doi:10.1016/j.cllc.2016.03.004

    authors: Wu FZ,Huang YL,Wu CC,Tang EK,Chen CS,Mar GY,Yen Y,Wu MT

    更新日期:2016-09-01 00:00:00

  • Treatment of patients excluded from Eastern Cooperative Oncology Group 4599 and AVAiL studies: focus on brain metastasis and squamous histology.

    abstract::Bevacizumab is the first molecularly targeted agent associated with improved outcomes in combination with chemotherapy in previously untreated patients with non-small-cell lung cancer (NSCLC). The addition of bevacizumab, a monoclonal antibody against vascular endothelial growth factor (VEGF), to carboplatin and pacli...

    journal_title:Clinical lung cancer

    pub_type: 杂志文章,评审

    doi:10.3816/CLC.2008.s.009

    authors: Morgensztern D,Govindan R

    更新日期:2008-03-01 00:00:00

  • Placebo-controlled trial of bexarotene, a retinoid x receptor agonist, as maintenance therapy for patients treated with chemotherapy for advanced non-small-cell lung cancer.

    abstract::This study was designed as a multicenter, randomized, double-blind, placebo-controlled trial. Patients were randomized by center to placebo (16 patients, 31%), oral bexarotene 300 mg/m2/day (21 patients, 40%), or oral bexarotene 600 mg/m2/day (15 patients, 29%) following demonstration of stable or responsive disease a...

    journal_title:Clinical lung cancer

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.3816/clc.2001.n.005

    authors: Rizvi N,Hawkins MJ,Eisenberg PD,Yocum RC,Reich SD,Ligand L1069-20 Working Group.

    更新日期:2001-02-01 00:00:00

  • Phase II study of sequential treatment of advanced non-small-cell lung cancer: three cycles of high-dose epirubicin plus cisplatin followed by weekly vinorelbine.

    abstract::Previous phase I, II, and III studies on high-dose epirubicin (HDEPI), alone or in combination with cisplatin (CP), indicate an interesting activity of this drug in the treatment of non-small-cell lung cancer (NSCLC). However, the toxicological profile of HDEPI limits its prolonged use. In our experience, vinorelbine ...

    journal_title:Clinical lung cancer

    pub_type: 杂志文章

    doi:10.3816/clc.2001.n.017

    authors: Guaraldi M,Marino A,Pannuti F,Farabegoli G,Martoni A

    更新日期:2001-08-01 00:00:00

  • Location Matters: Stage I Non-Small-cell Carcinomas of the Lower Lobes Treated With Stereotactic Body Radiation Therapy Are Associated With Poor Outcomes.

    abstract:INTRODUCTION:The lung is a heterogeneous organ with relative overperfusion of the lung bases. We determined whether a lower lobe primary tumor location was associated with poor outcomes in the setting of stage I non-small-cell lung cancer (NSCLC) treated with stereotactic body radiation therapy (SBRT). PATIENTS AND ME...

    journal_title:Clinical lung cancer

    pub_type: 杂志文章

    doi:10.1016/j.cllc.2016.09.001

    authors: Shaverdian N,Veruttipong D,Wang J,Kupelian P,Steinberg M,Lee P

    更新日期:2017-03-01 00:00:00

  • Tumor Microenvironment Properties are Associated With Low CD68-positive Cell Infiltration and Favorable Disease-free Survival in EGFR-mutant Lung Adenocarcinoma.

    abstract:BACKGROUND:The benefits of immune checkpoint inhibitors for first-line treatment in patients with lung adenocarcinoma harboring EGFR mutations are unclear. The effects of ICIs depend on the tumor microenvironment (TME). Differences in TME properties between mutant and wild-type EGFR have not been fully characterized. ...

    journal_title:Clinical lung cancer

    pub_type: 杂志文章

    doi:10.1016/j.cllc.2018.03.011

    authors: Gong Z,Chen J,Cheng JN,Sun C,Jia Q,Diao X,Zhu B

    更新日期:2018-09-01 00:00:00

  • Clinical significance of the serum crosslinked N-telopeptide of type I collagen as a prognostic marker for non-small-cell lung cancer.

    abstract:INTRODUCTION:Lung cancer is the leading cause of cancer-related death. Many patients with lung cancer are in its advanced stages at the time of diagnosis. The 5-year survival rate for lung cancer is 10% to 20%, and the prognosis for patients with lung cancer is still poor. The crosslinked N-terminal telopeptide of type...

    journal_title:Clinical lung cancer

    pub_type: 杂志文章

    doi:10.1016/j.cllc.2012.03.012

    authors: Tamiya M,Kobayashi M,Morimura O,Yasue T,Nakasuji T,Satomu M,Kohei O,Takayuki S,Morishita N,Suzuki H,Sasada S,Okamoto N,Hirashima T,Kawase I

    更新日期:2013-01-01 00:00:00

  • Small-cell carcinoma with an epidermal growth factor receptor mutation in a never-smoker with gefitinib-responsive adenocarcinoma of the lung.

    abstract::Activating mutations in the epidermal growth factor receptor (EGFR) gene are extremely rare in small-cell lung cancer (SCLC). Here, we present a case of an EGFR-mutant gefitinib-responsive non-small-cell lung cancer (NSCLC) of adenocarcinoma histology occurring in a never-smoker followed by subsequent diagnosis of met...

    journal_title:Clinical lung cancer

    pub_type: 杂志文章

    doi:10.3816/CLC.2010.n.046

    authors: Alam N,Gustafson KS,Ladanyi M,Zakowski MF,Kapoor A,Truskinovsky AM,Dudek AZ

    更新日期:2010-09-01 00:00:00

  • The emerging role of biomarkers in advanced non-small-cell lung cancer.

    abstract::Novel therapies, particularly those that target vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR), have improved the treatment of advanced non-small-cell lung cancer (NSCLC). The search continues for biomarkers that can predict which patients are most likely to benefit from these th...

    journal_title:Clinical lung cancer

    pub_type: 杂志文章,评审

    doi:10.3816/CLC.2010.n.019

    authors: Socinski MA

    更新日期:2010-05-01 00:00:00

  • Clinical significance of downstaging in patients with limited-disease small-cell lung cancer.

    abstract:BACKGROUND:We investigated the effect of downstaging on OS in LD-SCLC patients treated with first-line treatment. PATIENTS AND METHODS:We retrospectively reviewed 210 LD-SCLC patients who were treated with first-line treatment at Seoul National University Hospital between April 1999 and November 2012. Compared with in...

    journal_title:Clinical lung cancer

    pub_type: 杂志文章

    doi:10.1016/j.cllc.2013.09.003

    authors: Go SI,Keam B,Kim TM,Lee SH,Kim DW,Kim HJ,Wu HG,Chung DH,Heo DS

    更新日期:2014-03-01 00:00:00

  • Detection of EGFR-Activating and T790M Mutations Using Liquid Biopsy in Patients With EGFR-Mutated Non-Small-Cell Lung Cancer Whose Disease Has Progressed During Treatment With First- and Second-Generation Tyrosine Kinase Inhibitors: A Multicenter Real-Li

    abstract:BACKGROUND:In advanced epidermal growth factor receptor (EGFR)-mutated non-small-cell lung cancer (NSCLC) patients whose disease has progressed during treatment with first- and second-generation tyrosine kinase inhibitors (TKIs), liquid biopsy (LB) is routinely used to evaluate the presence of EGFR T790M as an acquired...

    journal_title:Clinical lung cancer

    pub_type: 杂志文章

    doi:10.1016/j.cllc.2020.02.021

    authors: Minari R,Mazzaschi G,Bordi P,Gnetti L,Alberti G,Altimari A,Gruppioni E,Sperandi F,Parisi C,Guaitoli G,Bettelli S,Longo L,Bertolini F,Pagano M,Bonelli C,Tagliavini E,Nicoli D,Ubiali A,Zangrandi A,Trubini S,Proietto

    更新日期:2020-09-01 00:00:00

  • Pathological examination and the reporting of lung cancer specimens.

    abstract::The Lung Cancer Disease Site Group (DSG) of the Cancer Care Ontario Practice Guidelines Initiative first met in January of 1994. Included in the membership were three pathologists who, with the other members of the DSG, felt that a useful contribution to the work of the group would be a recommendation on standardized ...

    journal_title:Clinical lung cancer

    pub_type: 杂志文章

    doi:10.3816/clc.2000.n.008

    authors: Chamberlain DW,Wenckebach GF,Alexander F,Fraser RS,Kolin A,Newman T

    更新日期:2000-05-01 00:00:00